Dataset Information

Murphy2016 - Differences in predictions of ODE models of tumor growth

ABSTRACT: Murphy2016 - Differences in predictions of ODE models of tumor growth Comparison of 7 ODE models for tumour size. This models have been compared to experimental data. This model is described in the article: Differences in predictions of ODE models of tumor growth: a cautionary example. Murphy H, Jaafari H, Dobrovolny HM. BMC Cancer 2016 Feb; 16: 163 Abstract: While mathematical models are often used to predict progression of cancer and treatment outcomes, there is still uncertainty over how to best model tumor growth. Seven ordinary differential equation (ODE) models of tumor growth (exponential, Mendelsohn, logistic, linear, surface, Gompertz, and Bertalanffy) have been proposed, but there is no clear guidance on how to choose the most appropriate model for a particular cancer.We examined all seven of the previously proposed ODE models in the presence and absence of chemotherapy. We derived equations for the maximum tumor size, doubling time, and the minimum amount of chemotherapy needed to suppress the tumor and used a sample data set to compare how these quantities differ based on choice of growth model.We find that there is a 12-fold difference in predicting doubling times and a 6-fold difference in the predicted amount of chemotherapy needed for suppression depending on which growth model was used.Our results highlight the need for careful consideration of model assumptions when developing mathematical models for use in cancer treatment planning. This model is hosted on BioModels Database and identified by: BIOMD0000000671. To cite BioModels Database, please use: Chelliah V et al. BioModels: ten-year anniversary. Nucl. Acids Res. 2015, 43(Database issue):D542-8. To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

SUBMITTER: Emma Fairbanks

PROVIDER: BIOMD0000000671 | BioModels | 2024-09-02

REPOSITORIES: BioModels

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	BIOMD0000000671?filename=BIOMD0000000671-biopax2.owl	Owl
	BIOMD0000000671?filename=BIOMD0000000671-biopax3.owl	Owl
	BIOMD0000000671?filename=BIOMD0000000671.m	Other
	BIOMD0000000671?filename=BIOMD0000000671.pdf	Pdf
	BIOMD0000000671?filename=BIOMD0000000671.png	Other

Items per page:

1 - 5 of 13

Publications

Differences in predictions of ODE models of tumor growth: a cautionary example.

Murphy Hope H Jaafari Hana H Dobrovolny Hana M HM

BMC cancer 20160226

<h4>Background</h4>While mathematical models are often used to predict progression of cancer and treatment outcomes, there is still uncertainty over how to best model tumor growth. Seven ordinary differential equation (ODE) models of tumor growth (exponential, Mendelsohn, logistic, linear, surface, Gompertz, and Bertalanffy) have been proposed, but there is no clear guidance on how to choose the most appropriate model for a particular cancer.<h4>Methods</h4>We examined all seven of the previousl ...[more]

PMID: 26921070

Similar Datasets

Project description:BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is unique for its high stromal components play important role for tumor progression and therapeutic resistance. However, relevant preclinical models that recapitulate these tumor microenvironment are lacking and how the differences in the microenvironment affect cancer cell behavior are poorly understood. Here, we investigated the effects of tumor microenvironment on cancer cells behavior and therapeutic response. METHODS: Previously established two behaviorally distinct patient-derived tumor xenografts (PDTX) models (moderate: PAC006 and poorly differentiated: PAC010) were re-implanted in Nude mice. Tumor volume, histology, immuno-histochemical, RNA sequencing and other molecular technique were used to characterize the models and study the effect of two classes of drugs (Gemcitabine (nucleoside analog) and Acriflavine (HIF-inhibitor)). RESULTS: -Models- The models recapitulated the histologic, genetic and biological characteristics of the corresponding primary tumors except the replacement of human stroma with mice stroma. The growth-rate of the tumors was significantly different between both models (cell doubling time, PAC006: 5.8 days vs PAC010: 3.6 days, p=0.005). Rapid tumor growth was associated with poor tumor differentiation that may reflect the ability of our PDTX models to mimic the cellular and non-cellular features of the parental tumor. At the molecular level, the poorly differentiated model showed increased Ki-67 staining and higher phosphorylation levels of AKT, ERK and NF-kB65. In addition, RT-qPCR, NGS and protein expression showed significant up-regulation of mesenchymal markers in tumor cells (e.g. VIM, SNAI2, HIF1A and TGF-β1) and growth factors and cytokines in mice stroma. RNA sequencing analysis from tumor cells and stroma demonstrated activation of pathways related to tumor progression and aggressiveness in PAC010 compared to PAC006. Gemcitabine treatment resulted in a shrinking of the tumor and reduction of proliferation in both models. Interestingly, gemcitabine treatment also significantly enhanced the expression of mesenchymal marker (e.g. VIM, SNAI2, SPARC, ZEB1), particularly in the well-moderately differentiated tumor model. Acriflavine had little effect on tumor growth in both models.

Project description:Ribba2012 - Low-grade gliomas, tumour growth inhibition model Using longitudinal mean tumour diameter (MTD) data, this model describe the size evolution of low-grade glioma (LGG) in patients treated with chemotherapy or radiotherapy. This model is described in the article: A tumour growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy Ribba B, Kaloshi G, Peyre M, Ricard D, Calvez V, Tod M, Cajavec-Bernard B, Idbaih A, Psimaras D, Dainese L, Pallud J, Cartalat-Carel S, Delattre JY, Honnorat J, Grenier E, Ducray F. Clin. Cancer Res. 2012 Sep; 18(18): 5071-5080 Abstract: PURPOSE: To develop a tumor growth inhibition model for adult diffuse low-grade gliomas (LGG) able to describe tumor size evolution in patients treated with chemotherapy or radiotherapy. EXPERIMENTAL DESIGN: Using longitudinal mean tumor diameter (MTD) data from 21 patients treated with first-line procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine (PCV) chemotherapy, we formulated a model consisting of a system of differential equations, incorporating tumor-specific and treatment-related parameters that reflect the response of proliferative and quiescent tumor tissue to treatment. The model was then applied to the analysis of longitudinal tumor size data in 24 patients treated with first-line temozolomide (TMZ) chemotherapy and in 25 patients treated with first-line radiotherapy. RESULTS: The model successfully described the MTD dynamics of LGG before, during, and after PCV chemotherapy. Using the same model structure, we were also able to successfully describe the MTD dynamics in LGG patients treated with TMZ chemotherapy or radiotherapy. Tumor-specific parameters were found to be consistent across the three treatment modalities. The model is robust to sensitivity analysis, and preliminary results suggest that it can predict treatment response on the basis of pretreatment tumor size data. CONCLUSIONS: Using MTD data, we propose a tumor growth inhibition model able to describe LGG tumor size evolution in patients treated with chemotherapy or radiotherapy. In the future, this model might be used to predict treatment efficacy in LGG patients and could constitute a rational tool to conceive more effective chemotherapy schedules. This model is hosted on BioModels Database and identified by: BIOMD0000000521 . To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models . To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.